Legal & General Group PLC Passage Bio, Inc. Transaction History

Legal & General Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.22 - $2.48 $3,612 - $7,343	-2,961 Closed	0 $0
Q2 2022 Aug 22, 2022	SELL	$1.63 - $3.46 $8,629 - $18,317	-5,294 Reduced 64.13%	2,961 $7,000
Q3 2021 Nov 15, 2021	BUY	$9.73 - $15.52 $45,789 - $73,037	4,706 Added 132.6%	8,255 $82,000
Q2 2021 Aug 12, 2021	SELL	$12.44 - $19.45 $4,764 - $7,449	-383 Reduced 9.74%	3,549 $47,000
Q1 2021 May 17, 2021	BUY	$16.24 - $29.83 $12,407 - $22,790	764 Added 24.12%	3,932 $68,000
Q4 2020 Feb 12, 2021	BUY	$14.28 - $29.73 $15,279 - $31,811	1,070 Added 51.0%	3,168 $81,000
Q3 2020 Nov 13, 2020	SELL	$12.39 - $26.15 $6,591 - $13,911	-532 Reduced 20.23%	2,098 $28,000
Q2 2020 Aug 14, 2020	BUY	$14.59 - $36.07 $38,371 - $94,864	2,630 New	2,630 $72,000

32.7M

8.3K

400

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.9M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.